Vimseltinib for patients with tenosynovial giant cell tumor: A multicenter, open-label, phase 2 trial
Pooled safety of vimseltinib in patients with tenosynovial giant cell tumor who received no prior colony-stimulating factor 1 receptor inhibitor therapy
Exposure-Response Analyses for Vimseltinib in Patients With Tenosynovial Giant Cell Tumor
Population Pharmacokinetic Analyses of Vimseltinib in Healthy Volunteers and Patients With Solid Tumors or Tenosynovial Giant Cell Tumor
A Phase 2, Open Label Study to Evaluate Vimseltinib in Adults with Active Chronic Graft-Versus-Host Disease after Failure of Prior Systemic Therapies
Mixed-Methods to Define Meaningful Change using Exit Interview and Clinical Trial Data in Patients with Tenosynovial Giant Cell Tumor (TGCT)
Effect of itraconazole and rabeprazole on the pharmacokinetics of vimseltinib, an oral inhibitor of the colony-stimulating factor 1 receptor, in healthy participants
